About Ardelyx
Ardelyx is a publicly listed company based in Fremont (United States) founded in 2007 by Peter G Schultz. Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. Ardelyx has raised $61.1 million across 8 funding rounds from investors including Western Alliance Bank, RA Capital and SLR Investment Corp. The company has 395 employees. Its chief executive, as recorded, is Mike Raab. Its website ardelyx.com draws about 18 thousand monthly visits. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is ARDELYX, INC. Its competitors include Ironwood Pharma, DermBiont and Alcresta; 3 of its 3 listed competitors have raised funding.
Company details
Ardelyx was founded in 2007 and is based in Fremont, United States. Focus is placed on developing therapeutics targeting the gastrointestinal tract for conditions including cardio-renal, GI, and metabolic diseases. The lead product, Tenapanor, is advanced as a sodium transport inhibitor for irritable bowel syndrome with constipation and hyperphosphatemia in dialysis patients. Additional efforts involve RDX002 for hyperkalemia treatment in kidney and heart disease patients.
- Headquarters Fremont, United States
- Employees 395
- Founders Peter G Schultz
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website ardelyx.com
- Social LinkedIn X Facebook
- Legal Name Ardelyx, Inc.
- Annual Revenue$407.32 M (USD)22.09as on Dec 31, 2025
- Net Profit-$61.6 M (USD)-57.4as on Dec 31, 2025
- EBITDA-$37.92 M (USD)-46.48as on Dec 31, 2025
- Total Equity Funding$61.1M (USD)
in 8 rounds
- InvestorsWestern Alliance Bank
& 10 more
- Employee Count395
Funding Insights of Ardelyx
Ardelyx has successfully raised a total of $61.1M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61.1M
- Total Rounds 8
- First Round $26.09M
(Jun 2008)
- Investors Count 11
All 8 funding rounds of Ardelyx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | Post-IPO | – | – | ||
| Nov 2019 | $20M | Post-IPO | – | – | |
| May 2018 | $50M | Debt – Conventional | – | – | |
| Jul 2016 | $110M | Post-IPO | – | – | – |
| Jun 2015 | $77.77M | Post-IPO | – | – | |
| Aug 2011 | $30M | Series B | – | New Enterprise Associates, CMEA Capital | – |
| Dec 2010 | $5.01M | Series A | – | – | – |
| Jun 2008 | $26.09M | Series A | – | – | – |
11 investors in total: 11 institutional.
Investors in Ardelyx
Ardelyx has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Western Alliance Bank, RA Capital and SLR Investment Corp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
Debt and equity investments are offered by the firm. | 2006 | solarcapltd.com | New York, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
| cmea.com | ||||
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Commercial banking services, including loans and treasury management, are provided. | 2001 | westernalliancebancorporation.com | Phoenix, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Ardelyx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ardelyx
83 people are tracked at Ardelyx (66 in leadership, 2 in board & advisors, 15 in team); the tracked headcount is 395.
| Name | Role | Group |
|---|---|---|
Peter G Schultz | Co-Founder | Leadership |
Mike Raab | CEO | Leadership |
Sandra Oyakawa | Area Business Director | Leadership |
Tim Garver | Area Business Director | Leadership |
Meg Fisher | Area Business Director | Leadership |
Maggie Marcoux | Vice President, Finance | Leadership |
Nathan Newell | Area Business Director, SE Regional Lead | Leadership |
Kara Davis | Business Area Director | Leadership |
Alicia Burt | Area Business Director | Leadership |
Caryn Neidel | Associate Director, Marketing | Leadership |
Kenji Kozuka | Senior Director, Preclinical Research And Nonclinical Development | Leadership |
Evyn Rabinowitz | Senior Director, Corporate Securities and Governance Counsel | Leadership |
Mike Namorato | Associate Director, Compliance | Leadership |
Anne Marie Ryberg | Sr. Director, Global Marketing & New Product Planning | Leadership |
Jody Doucette | Senior Director Of Marketing | Leadership |
Justin Ingram | Business Area Director | Leadership |
Lily Yan | Director, Financial Planning And Analysis | Leadership |
Brandon Marsh | Senior Director, Corporate And Business Development, Legal | Leadership |
Houston Stephens | Area Business Director | Leadership |
Caitlin Lowie | VP, Corporate Communications and Investor Relations | Leadership |
63 more people are available in the full profile.
Complete people profiles for Ardelyx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ardelyx
Ardelyx is a publicly listed company on the NASDAQ with ticker symbol ARDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Jun 2014
- Listed onNASDAQ: ARDX
- Listed entityArdelyx, Inc.
- Exchange sectorHealth technology
- ISINUS0396971071
- Share price$3.12 (-3.41% on the day) · 2026-10-13
- Market capitalisation$777.5M
- EPS (diluted, trailing year)$-0.23
- Volume (last session)6,872,758
Financials of Ardelyx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $407.3M | -$61.6M | -$37.9M |
| 2024 | $333.6M | -$39.1M | -$25.9M |
| 2023 | $124.5M | -$66.1M | -$62.0M |
| 2022 | $52.2M | -$67.2M | -$59.2M |
| 2021 | $10.1M | -$158.2M | -$149.8M |
Detailed financial statements for Ardelyx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ardelyx
4 dated milestones of Ardelyx across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Ardelyx is founded.
- Funding First funding round of $26.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Ardelyx
Ardelyx has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, DermBiont and Alcresta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. |
Detailed competitors of Ardelyx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ardelyx
The website of Ardelyx (ardelyx.com) receives about 17.8K visits a month and ranks #2,305,983 among all websites worldwide, #3,158 in Biotechnology and Pharmaceuticals.
- Monthly visits17.8K
▲ 74.1% vs previous month
- Unique visitors4.8K
per month
- Global rank#2,305,983
among all websites
- Category rank#3,158
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.5
- Average visit5 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Ardelyx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| achaogen.com | 100% | View details | |||
| medreich.com | 95% | 1.9K | #7,047,446 | View details | |
| dermira.com | 93% | View details | |||
| ocutx.com | 93% | 12.7K | #1,928,176 | View details | |
eftc-europe.com | eftc-europe.com | 58% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Ardelyx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Ardelyx (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ardelyx
Complete news archive for Ardelyx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ardelyx
Ardelyx was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Ardelyx is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Mike Raab is the CEO of Ardelyx, as recorded in our data.
Ardelyx is a funded company, having raised a total of $61.1M across 8 funding rounds to date. The company's 1st funding round was a Series A of $26.09M, raised on Jun 2008.
Ardelyx has 395 employees.
Annual revenue of Ardelyx is $407.32M as on Dec 31, 2025.
Ardelyx was founded in 2007 and is based in Fremont, United States. Focus is placed on developing therapeutics targeting the gastrointestinal tract for conditions including cardio-renal, GI, and metabolic diseases. The lead product, Tenapanor, is advanced as a sodium transport inhibitor for irritable bowel syndrome with constipation and hyperphosphatemia in dialysis patients. Additional efforts involve RDX002 for hyperkalemia treatment in kidney and heart disease patients.
Ardelyx's top competitors include Ironwood Pharma, DermBiont and Alcresta.
Yes, Ardelyx is publicly traded on NASDAQ under the ticker symbol ARDX.
Ardelyx has 11 investors. Key investors include Western Alliance Bank, RA Capital, SLR Investment Corp, Kyowa Kirin, and HealthCare Royalty Partners.
Ardelyx operates through Ardelyx, Inc..